Kevin P. Shah kevin.shah.wg11@wharton.upenn.edu


Penn State University, University Park, PA B.S., Highest Distinction, Bioengineering, 2006 University of Pennsylvania, School of Medicine Philadelphia, PA M.D. Candidate, 2011


Sejal D. Shah sejal.shah.wg11@wharton.upenn.edu


Duke University, Durham, NC B.S., Biology, 2005 B.A., Economics, 2005


Bhuvan Srinivasan bhuvan.srinivasan.wg11@wharton.upenn.edu


Johns Hopkins University, Baltimore, MD B.S. and M.S.E., Tau Beta Pi, Biomedical Engineering with Concentration in Electrical Engineering, 2005


An opportunity to use my medical and business background to improve both the financing and delivery of clinical care.


McKinsey & Company, New York, NY Summer Associate, Summer 2010 Designed and began implementation of new financing models for clinical care at a major private payer. Developed baseline understanding of variability in cost and quality of care across numerous hospitals. Helped define a bundled payment model for certain types of surgery and mapped the operational capabilities necessary to implement these new payment models.


Navigant Consulting, Princeton, NJ Summer Associate, Summer 2010 Worked on a due diligence for a major pharmaceutical company looking to make a multi-billion dollar acquisition. Developed a revenue fore- cast for the target company, modeling the competitive landscape of multiple products in this clinical area. Worked with another pharmaceutical company designing and implementing a quantitative survey to model uptake of a new product.


Kaplan Inc., Philadelphia, PA 2004-Present Work as an MCAT instructor, teaching both classroom and private tutoring. Ranked among the best teachers in the Philadelphia region, per student evaluation.


An opportunity to leverage my consulting background and corporate strategy experience to provide strategic leadership at an innovative health care company.


McKesson Corporation, San Francisco, CA


Intern, Corporate Strategy and Business Development, Summer 2010


Evaluated strategic opportunities to use a specific technology for clinical trials. Identified and prioritized several short and long-term options and developed recommendations and business case around one opportunity. Delivered recommendations to senior management and chief executives.


Stockamp Practice, Huron Consulting Group, Lake Oswego, OR Associate, 2007-2009 Analyst, 2005-2007


Led crossfunctional teams to design and implement strategic and opera- tional patient flow and capacity man- agement projects in large academic medical centers. On last engagement, managed two analysts leading to 12% improvement in on-service patients upon admission and 6.8 hour average length of stay decrease. Concurrently managed director-level administrative and clinical relationships to gain buy-in and streamline communication for operational initiatives.


An opportunity in principal investing.


Baring Private Equity Asia, Mumbai, India


Summer Associate, Summer 2010 Conducted deal evaluation of $600M IT company and developed restructur- ing plan for $300M of debt. Led sector study for investment opportunities in consumer products. Identified F&B, consumer pharmaceuticals and branded liquor as attractive sub-sectors based on size, growth, profitability, competition, and pricing power.


Bain & Company, Singapore Senior Associate Consultant, 2007-2009 Crafted strategy for global companies and conducted commercial due diligence for private equity firms. Advised on business unit growth and market entry strategy for global agri-commodities trading firm (Singapore). Evaluated merger of $10B food company with rival to create global leader in vegetable oils (Malaysia). Created Financial Services investment strategy for Sovereign Wealth Fund (Abu Dhabi).


Medtronic Diabetes, Northridge, CA Biomedical Engineer (R&D), 2005-2007 Accelerated launch of real-time glucose sensor by one year by contributing in all stages of device lifecycle, including focus groups for interface design, software and hardware testing, prototyping, and production line troubleshooting. Led creation of accelerated aging models to double device life to 24 months.


26


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40